Sonida Senior Living (NYSE:SNDA) has completed its acquisition of CNL Healthcare Properties (CHP) in a cash-and-stock transaction valued at approximately $1.8 billion.
Tredegar (NYSE:TG) reported a sharp recovery in its fourth-quarter financial results, posting net income from continuing operations of $14.5 million, or $0.42 per diluted share.
T. Rowe Price Group (NASDAQ:TROW) reported preliminary month-end assets under management of $1.803 trillion for February 2026, a marginal increase from the $1.797 trillion recorded at the end of January.
Target Hospitality (NASDAQ:TH), North America’s largest provider of specialty rental accommodations and hospitality services, reported financial results for the fourth quarter and full year ended December 31, 2025.
Acacia Research (NASDAQ:ACTG), a diversified holding company that acquires and operates businesses across the industrial and technology sectors, reported fourth-quarter and full-year 2025 financial results on Wednesday.
Minerva Neurosciences (NASDAQ:NERV), a biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, reported a net loss of $283.7 million for the fourth quarter ended December 31, 2025.
Kamada (NASDAQ:KMDA), a vertical integrated biopharmaceutical company specializing in plasma-derived therapeutics, reported fourth-quarter and full-year 2025 financial results on Wednesday.
Verrica Pharmaceuticals (NASDAQ:VRCA), a dermatology-focused therapeutics company, reported financial results for the fourth quarter and full year ended December 31, 2025, on Wednesday.
Sonida Senior Living (NYSE:SNDA), an owner and operator of senior housing communities, announced its financial results for the fourth quarter and full year ended December 31, 2025, on Wednesday.
Sagimet Biosciences (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors, reported its fourth-quarter and full-year 2025 financial results on Wednesday.
BrainsWay (NASDAQ:BWAY), a global leader in advanced non-invasive neurostimulation treatments, reported robust financial results for the fourth quarter and full year ended December 31, 2025.
60 Degrees Pharmaceuticals (NASDAQ:SXTP), a specialist in medicines for vector-borne diseases, announced Wednesday that all three patients enrolled in its expanded-use clinical trial for relapsing babesiosis were successfully cured.
